Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant ASCENT: A Phase II Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma SMM
A Phase II, Open-Label, Multicenter Study of Arlocabtagene Autoleucel BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma. QUINTESSENTIAL
A Measurable Residual Disease MRD Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
A Phase I Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
A Phase IB/II, Open Label, Umbrella Study Of Elranatamab PF06863135, A B-Cell Maturation Antigen BCMA CD3 Bispecific Antibody, In Combination With Other Anticancer Treatments In Participants With Multiple Myeloma
A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia, Intermediate or Higher-Risk Myelodysplastic Syndromes, bcr-abl negative Myeloproliferative, Myelodysplastic/Myeloproliferative Neoplasms and Multiple Myeloma